Essra Ridha
Corporate Officer/Principal bij The Royal College of Physicians
Vermogen: 23 504 $ op 31-05-2024
Actieve functies van Essra Ridha
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| The Royal College of Physicians | Corporate Officer/Principal | - | - |
Loopbaan van Essra Ridha
Eerdere bekende functies van Essra Ridha
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Hoofd Techniek/Wetenschap/O&O | 01-10-2021 | 20-06-2024 |
| TECTONIC THERAPEUTIC, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2021 | 01-07-2021 |
| SANGAMO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-06-2019 | 01-02-2021 |
Opleiding van Essra Ridha
| Royal Free Hospital Medical School | Doctorate Degree |
| UCL Medical School | Doctorate Degree |
| University College London | Undergraduate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 5 |
| Verenigde Staten | 3 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Consumer Services | 5 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Beurs
- Insiders
- Essra Ridha
- Ervaring
